[HTML][HTML] Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Chronic liver disease (CLD) is a continuous process that causes a reduction of liver function
lasting more than six months. CLD includes alcoholic liver disease (ALD), non-alcoholic fatty …
lasting more than six months. CLD includes alcoholic liver disease (ALD), non-alcoholic fatty …
Pharmacological support for the treatment of obesity—present and future
M Kosmalski, K Deska, B Bąk, M Różycka-Kosmalska… - Healthcare, 2023 - mdpi.com
Obesity is a growing civilization problem, associated with a number of negative health
consequences affecting almost all tissues and organs. Currently, obesity treatment includes …
consequences affecting almost all tissues and organs. Currently, obesity treatment includes …
[HTML][HTML] Effects of telmisartan on metabolic syndrome components: a comprehensive review
M Imenshahidi, A Roohbakhsh… - Biomedicine & …, 2024 - Elsevier
Telmisartan is an antagonist of the angiotensin II receptor used in the management of
hypertension (alone or in combination with other antihypertensive agents. It belongs to the …
hypertension (alone or in combination with other antihypertensive agents. It belongs to the …
How far are we from an approved drug for nonalcoholic steatohepatitis?
N Méndez-Sánchez, SC Pal… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Metabolic-associated fatty liver disease (MAFLD) previously known but still
debatable, as nonalcoholic fatty liver disease (NAFLD) is one of the main causes of chronic …
debatable, as nonalcoholic fatty liver disease (NAFLD) is one of the main causes of chronic …
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled …
H Wang, Q Ma, Y Chen, L Luo, J Ye… - Obesity …, 2024 - Wiley Online Library
Background Emerging treatment methods, including exercise, diet, and drugs, for
nonalcoholic fatty liver disease have been proposed. However, the differences in their …
nonalcoholic fatty liver disease have been proposed. However, the differences in their …
[HTML][HTML] Effectiveness of lifestyle interventions for nonalcoholic fatty liver disease treatment
A Arredouani - Lifestyle-related diseases and metabolic syndrome, 2022 - intechopen.com
The prevalence of nonalcoholic fatty liver disease (NAFLD), which affects around 25% of the
world's population, has been rapidly rising along with the rate of obesity in the world. NAFLD …
world's population, has been rapidly rising along with the rate of obesity in the world. NAFLD …
[PDF][PDF] TESIS DE POSGRADO
EDELAC DE ORLISTAT - 2023 - ru.dgb.unam.mx
La epidemia de S/O es un problema de salud pública (1) con efectos negativos a la salud.
Es el factor de riesgo más frecuente para las generar las NCD (2) que, junto con el cáncer …
Es el factor de riesgo más frecuente para las generar las NCD (2) que, junto con el cáncer …